Navigation Links
Access to environmental research in developing nations grown to 1,500 institutions
Date:5/14/2009

Amsterdam, 14 May 2009 Research4Life today announces that the Online Access to Research in the Environment (OARE) program has registered 1500 institutions since its launch in 2006, an increase of nearly 700 percent. This means that scientists, researchers and environmental policy-makers in 1,500 not-for-profit institutions in the world's poorest countries can gain free or low cost access to the latest environmental science literature from the world's leading journals, books and databases.

OARE's sister programs, HINARI Access to Research Initiative and Access to Global Online Research in Agriculture (AGORA), have also shown significant growth. Established in 2002, registrations for HINARI have grown by 61 percent since 2006 so that researchers at 3,866 not-for-profit institutions in 108 countries now have access to over 6,300 medical and health journals.

Registrations for AGORA (established in 2003) have increased by 77 percent since 2006, providing researchers at 1,760 developing world institutions with access to 1,276 food, agriculture, and related social sciences journals.

Research4Life is the collective name given to HINARI, AGORA and OARE, the three public-private partnership programs of the WHO, FAO, UNEP, Cornell and Yale Universities and the International Association of Scientific, Technical and Medical Publishers. 155 publishers now participate in the programs, including Elsevier, Wiley-Blackwell, Springer and many university and society presses. Together with technology partner Microsoft, Research4Life seeks to help achieve the UN's Millennium Development Goals by providing the developing world with access to critical up-to-date scientific research.

Mohammed Atani, OARE Technical Officer at the United Nations Environment Program, said: "It is positive to see the extent that developing nations are improving their research processes and creating expert professional and academic communities. By supporting scientific
'/>"/>

Contact: Shira Tabachnikoff
s.tabachnikoff@elsevier.com
31-204-852-736
Elsevier
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. AccessRx.com Provides Same-Day Shipping for Tamiflu, an Effective Treatment for Swine Flu
2. Access to care leads Americans priorities in first-ever public study of health value
3. Access to Care Leads Americans Priorities in First-Ever Public Study of Health Value
4. Ericoms Remote Access and Business Continuity Solution Increases Immunity to Productivity Losses -- Combats Swine Flu Scare
5. Alliance for Patient Access Wants Health Care Code of Conduct
6. Videoconferencing can increase patient access to stroke specialists
7. Accessible Air Travel Guide for People With Disabilities From United Spinal Association
8. 7 of 10 women are uninsured or underinsured, or have medical bill, debt, access problems
9. ChildCare Education Institute Gives Child Care Staff Access to Professional Development Courses in Honor of Provider Appreciation Day, May 8th
10. Security Officers Who Guard Kaiser Hospitals Protest Lack of Access to Affordable Healthcare
11. K-State Researchers and Their Partners Making it Easier for Rural Kansans of All Ages to Stay Healthy Despite Limited Access to Facilities Like Bike Trails, Gyms
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 2Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 3IEEE USA President endorses national innovation strategy 10050 1Utah ethicist heads stem cell panel 10048 1Utah ethicist heads stem cell panel 10048 2Utah ethicist heads stem cell panel 10048 3New beryllium reference material for occupational safety monitoring 10046 1New beryllium reference material for occupational safety monitoring 10046 2